452 studies found for:    Open Studies | Interventional Studies | melanoma
Show Display Options
Rank Status Study
21 Recruiting Hsp90 Inhibitor AT13387, Dabrafenib, and Trametinib in Treating Patients With Recurrent Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Conditions: Recurrent Melanoma;   Solid Neoplasm;   Stage IIIA Skin Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
Interventions: Drug: Dabrafenib;   Drug: Hsp90 Inhibitor AT13387;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Trametinib
22 Recruiting MART-1 Antigen With or Without TLR4 Agonist GLA-SE in Treating Patients With Stage II-IV Melanoma That Has Been Removed by Surgery
Conditions: Stage IIA Skin Melanoma;   Stage IIB Skin Melanoma;   Stage IIC Skin Melanoma;   Stage IIIA Skin Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
Interventions: Biological: MART-1 Antigen;   Drug: TLR4 Agonist GLA-SE;   Other: Laboratory Biomarker Analysis
23 Recruiting Immunotherapy Study for Patients With Stage IV Melanoma
Conditions: Stage IV Melanoma;   Metastatic Melanoma
Interventions: Drug: HyperAcute®-Melanoma (HAM) Immunotherapy;   Drug: Ipilimumab;   Drug: Pembrolizumab;   Drug: Nivolumab
24 Not yet recruiting Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases
Conditions: Metastatic Malignant Neoplasm in the Brain;   Metastatic Melanoma;   Mucosal Melanoma;   Ocular Melanoma;   Stage IV Non-Small Cell Lung Cancer;   Stage IV Skin Melanoma
Interventions: Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab;   Radiation: Stereotactic Radiosurgery
25 Recruiting Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery
Conditions: Metastatic Melanoma;   Stage IIIA Skin Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
Interventions: Drug: Dabrafenib;   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Drug: Trametinib
26 Recruiting Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumor Lysate or Homogenate Combined With Immunomodulating Radiotherapy and/or Preleukapheresis IFN-alfa in Patients With Metastatic Melanoma: a Randomized "Proof-of-principle" Phase II Study
Conditions: Malignant Melanoma of Skin Stage III;   Malignant Melanoma of Skin Stage IV
Interventions: Other: arm 1: DC Vaccine + RT;   Other: arm 2: DC Vaccine + IFN-alfa;   Other: arm 3: both arm 1 and 2 + RT;   Biological: arm 4: DC Vaccine
27 Recruiting Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma
Conditions: Recurrent Melanoma;   Stage IIIA Skin Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
Interventions: Drug: Dabrafenib;   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Other: Quality-of-Life Assessment;   Drug: Trametinib
28 Recruiting Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations
Conditions: Recurrent Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma
Interventions: Drug: trametinib;   Other: laboratory biomarker analysis;   Other: pharmacological study
29 Recruiting Vaccine Therapy in Treating Patients With Advanced Stage III-IV Melanoma
Conditions: Recurrent Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
Interventions: Biological: Recombinant Human Hsp110-gp100 Chaperone Complex Vaccine;   Other: Laboratory Biomarker Analysis
30 Recruiting Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma
Conditions: Adult Solid Neoplasm;   Recurrent Melanoma;   Stage IIIA Skin Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma
Interventions: Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Riluzole;   Drug: Sorafenib Tosylate
31 Recruiting Nivolumab and Ipilimumab With or Without Sargramostim in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
Conditions: Recurrent Melanoma of the Skin;   Stage IIIA Skin Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
Interventions: Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Biological: Sargramostim
32 Recruiting Pilot Study of Vigil™ + Pembrolizumab for Advanced Melanoma
Conditions: Melanoma Recurrent;   Malignant Melanoma;   Melanoma
Interventions: Biological: Vigil;   Drug: Pembrolizumab
33 Recruiting Sargramostim or Hypertonic Saline Before Sentinel Lymph Node Biopsy in Treating Patients With Stage IB-II Melanoma
Conditions: Stage IB Melanoma;   Stage IIA Melanoma;   Stage IIB Melanoma;   Stage IIC Melanoma
Interventions: Biological: sargramostim;   Procedure: sentinel lymph node biopsy;   Other: laboratory biomarker analysis;   Other: hypertonic saline
34 Unknown  Rituxan and Abraxane for the Treatment of Patients With Inoperable Stage III and IV Malignant Melanoma
Conditions: Malignant Melanoma of Skin Stage III;   Metastatic Melanoma
Intervention: Drug: Rituxan
35 Recruiting Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma
Conditions: Metastatic Ocular Melanoma;   Metastatic Uveal Melanoma
Interventions: Drug: Aldesleukin;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: Young TIL
36 Recruiting Pembrolizumab in Treating Patients With Advanced Uveal Melanoma
Conditions: Stage IIIA Uveal Melanoma;   Stage IIIB Uveal Melanoma;   Stage IIIC Uveal Melanoma;   Stage IV Uveal Melanoma
Interventions: Biological: Pembrolizumab;   Other: Laboratory Biomarker Analysis
37 Not yet recruiting Pembrolizumab and Imatinib in Patients With Locally Advanced/Metastatic Melanoma With c-KIT Mutation/Amplification
Conditions: Stage IIIA Skin Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
Interventions: Drug: Imatinib Mesylate;   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab
38 Recruiting Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic Melanoma
Conditions: Stage IIIA Skin Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
Interventions: Biological: Aldesleukin;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Biological: Therapeutic Tumor Infiltrating Lymphocytes
39 Recruiting Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib Plus Cobimetinib
Conditions: Metastatic Melanoma;   Melanoma;   BRAF-mutated Metastatic Melanoma;   V600EBRAF-mutated Metastatic Melanoma
Intervention: Drug: Vemurafenib + Cobimetinib, Decitabine
40 Not yet recruiting Ibrutinib in Treating Patients With Refractory Stage IV Cutaneous Melanoma
Conditions: Metastatic Melanoma;   Recurrent Melanoma of the Skin;   Stage IV Skin Melanoma
Interventions: Drug: Ibrutinib;   Other: Laboratory Biomarker Analysis;   Other: Pharmacogenomic Study

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years